{"id":"W2939153131","doi":"10.2340/00015555-3195","title":"Secukinumab Provides Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis: Patient Symptom Diary Data from Two Phase 3, Randomized, Placebo-controlled Clinical Trials","year":2019,"lang":"en","type":"article","venue":"Acta Dermato Venereologica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Allergan; LEO Pharma; Incyte; Sun Pharma; Regeneron Pharmaceuticals; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; National Psoriasis Foundation; Valeant Pharmaceuticals International; Endo International; Sanofi; Galderma; Ortho Dermatologics; Eli Lilly and Company; Amgen","keywords":"Secukinumab; Itching; Medicine; Placebo; Psoriasis; Randomized controlled trial; Clinical trial; Pain relief; Dermatology; Physical therapy; Alternative medicine; Surgery; Internal medicine; Psoriatic arthritis","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002108868,0.0008843737,0.002407297,0.0003387528,0.0003214356,0.0006929768,0.0005135637,0.001050043,0.003920123],"category_scores_gemma":[0.002022077,0.0003666376,0.001702427,0.0003633507,0.0005716491,0.0008777162,0.000207667,0.00193865,0.0004273997],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002501467,"about_ca_system_score_gemma":0.0003053617,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004388964,"about_ca_topic_score_gemma":0.001110661,"domain_scores_codex":[0.9994072,0.0003283123,0.00006078996,0.00006192529,0.00006779735,0.00007405462],"domain_scores_gemma":[0.9987451,0.0005999228,0.0002911542,0.00009191415,0.00007053703,0.0002015013],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8052526,0.01188876,0.003806995,0.003390033,0.003832556,0.0001340155,0.0002158377,0.0007902827,0.01374084,0.0001607286,0.002804065,0.1539834],"study_design_scores_gemma":[0.7934899,0.1657419,0.03328066,0.0001590917,0.00162899,0.0003255005,0.0001121091,0.0007282118,0.001724605,0.0002035552,0.002548117,0.00005740803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9689083,0.02472414,0.0009375609,0.000720463,0.0003395469,0.001057027,0.000836254,0.0001716956,0.002305063],"genre_scores_gemma":[0.989482,0.006629438,0.0007758973,0.0007190369,0.0002470323,0.0003788887,0.0007162145,0.00002122932,0.001030273],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003920123,"threshold_uncertainty_score":0.01311409,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03243579517012712,"score_gpt":0.2977604257043597,"score_spread":0.2653246305342326,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}